SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 10-QSB

(Mark  One)

         [X]      Quarterly report under Section 13 or 15(d) of the Securities
                  Exchange Act of 1934

                  FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2002

         [ ]      Transition report under Section 13 or 15(d) of the Exchange
                  Act

             For the transition period from __________ to __________

                         Commission file number 0-29489

                                MALACOLOGY, INC.
         --------------------------------------------------------------
        (Exact Name of Small Business Issuer as Specified in Its Charter)


          NEVADA                                               33-0850627
-------------------------------                                ----------
(State or Other Jurisdiction of                               (IRS Employer
Incorporation or Organization)                               Identification No.)


                        1101 Channelside Drive, Suite 241
                              Tampa, Florida 33602
                     --------------------------------------
                    (Address of Principal Executive Offices)


                                 (813) 864-3900
                 ----------------------------------------------
                (Issuer's Telephone Number, Including Area Code)


                                       N/A
               --------------------------------------------------
              (Former Name, Former Address and Former Fiscal Year,
                          If changed since Last Report)

         Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

         State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date: As of June 7, 2002 there
were 1,000,000 shares of common stock issued and outstanding, par value $0.001,
and no shares of preferred stock are issued and outstanding.

<PAGE>

                                MALACOLOGY, INC.

                                      INDEX

                                                                          Page

Part  I    Financial Information

Item  1.   Financial Statements

           Consolidated Balance Sheets as of March 31, 2002 (unaudited)
           and December 31, 2001                                            3

           Consolidated statements of operations for the three months
           ended March 31, 2002 and 2001, and for the period from
           inception, April 9, 1998, through March 31, 2002 (unaudited)     4

           Consolidated statements of cash flows for the three months
           ended March 31, 2002 and 2001, and for the period from
           inception, April 9, 1998, through March 31, 2002 (unaudited)     5

           Notes to consolidated financial statements                       6

Item  2.   Management's Discussion and Analysis or Plan of Operation       10

Part  II   Other Information                                               10

Item  1.   Legal Proceedings                                               10

Item  2.   Changes in Securities                                           10

Item  3.   Defaults Upon Senior Securities                                 10

Item  4.   Submission of Matters to a Vote of Security Holders             10

Item  5.   Other Information                                               10

Item  6.   Exhibits and Reports on Form 8-K                                11

<PAGE>
<TABLE>
<CAPTION>
                                        MALACOLOGY, INC.
                                (A Development Stage Enterprise)

                                   Consolidated Balance Sheets

                                             ASSETS

                                                                                 March 31, 2002    December 31, 2001
                                                                                   (unaudited)
                                                                                  -------------    ----------------
<S>                                                                               <C>              <C>
Cash                                                                              $          62    $          7,145
Other current assets                                                                      4,630              17,130
                                                                                  -------------    ----------------

           Total current assets                                                           4,692              24,275

Equipment, net of accumulated depreciation of $160 and $0,
  respectively                                                                            1,763               1,923
                                                                                  -------------    ----------------

           Total assets                                                           $       6,455    $         26,198
                                                                                  =============    ================

          LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Accrued expenses                                                                  $     103,527    $              -
Advances from officer                                                                   123,740             123,740
Convertible notes payable                                                                11,475              11,475
                                                                                  -------------    ----------------

           Total current liabilities                                                    238,742             135,215
                                                                                  -------------    ----------------

Convertible notes payable                                                               150,000             100,000
                                                                                  -------------    ----------------

           Total liabilities                                                            388,742             235,215
                                                                                  -------------    ----------------

Commitments

Stockholders' equity (deficit)
   Preferred stock, $0.001 par value; 2,000,000 shares
      authorized; no shares issued and outstanding                                            -                   -
   Common stock, $0.001 par value; 20,000,000 shares authorized;
      1,000,000 shares issued and outstanding                                             1,000               1,000
   Deficit accumulated during the development stage                                    (383,287)           (210,017)
                                                                                  -------------    -----------------

           Total stockholders' equity (deficit)                                        (382,287)           (209,017)
                                                                                  -------------    ----------------

           Total liabilities and stockholders' equity (deficit)                   $       6,455    $         26,198
                                                                                  =============    ================

                               See accompanying notes to consolidated financial statements

                                                            3
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
                                                MALACOLOGY, INC.
                                        (A Development Stage Enterprise)

                                      Consolidated Statements of Operations
                                                   (Unaudited)



                                                                                                    Period From
                                                                                                     Inception,
                                                           Three Months        Three Months        April 9, 1998,
                                                               Ended               Ended               Through
                                                             March 31,           March 31,            March 31,
                                                               2002                2001                 2002
                                                          ---------------    ----------------    ------------------
<S>                                                       <C>                <C>                  <C>
Consulting fees                                           $        (58,754)  $               -    $         (215,330)

General and administrative expenses                               (114,516)             (1,558)             (174,374)
                                                          ----------------   -----------------    ------------------

Loss before extraordinary item                                    (173,270)             (1,558)             (389,704)

Extraordinary item:
Gain on forgiveness of related party payable                             -                   -                 6,417
                                                          ----------------   -----------------    ------------------

Net loss                                                  $       (173,270)  $          (1,558)   $         (383,287)
                                                          ================   =================    ==================

Weighted average number of common shares
   outstanding                                                   1,000,000           1,000,000             1,000,000
                                                          ================   =================    ==================

Net loss per share                                        $          (0.17)  $           (0.00)   $            (0.38)
                                                          ================   =================    ==================

                                See accompanying notes to consolidated financial statements

                                                           4
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
                                                MALACOLOGY, INC.
                                        (A Development Stage Enterprise)

                                     Consolidated Statements of Cash Flows
                                                   (Unaudited)

                                                                                                    Period From
                                                                                                     Inception,
                                                           Three Months       Three Months         April 9, 1998,
                                                               Ended               Ended               Through
                                                             March 31,          March  31,            March 31,
                                                               2002                2001                 2002
                                                          ---------------    ----------------    ------------------
<S>                                                       <C>                <C>                  <C>
Cash flows from operating activities
   Net loss                                               $      (173,270)   $         (1,558)    $        (383,287)
   Adjustments to reconcile net loss to net cash
      used by operating activities
        Depreciation expense                                          160                   -                   160
        Issuance of common stock for services                           -                   -                 1,000
        Decrease (increase) in other current assets                12,500                   -                (4,630)
        Increase in accrued expenses                              103,527                   -               103,527
        (Decrease) increase in payable to
            related party                                               -               1,558                     -
                                                          ---------------    ----------------     -----------------

               Net cash used by operating
                 activities                                       (57,083)                  -              (283,230)
                                                          ---------------    ----------------     -----------------

Cash flows from investing activities
    Acquisition of equipment                                            -                   -                (1,923)
                                                          ---------------    ----------------     -----------------

Cash flows from financing activities
   Advances from officer                                                -                   -               123,740
   Proceeds from convertible notes payable                         50,000                   -               161,475
                                                          ---------------    ----------------     -----------------

               Net cash provided by financing
                 activities                                        50,000                   -               285,215
                                                          ---------------    ----------------     -----------------

Net (decrease) increase in cash                                    (7,083)                  -                    62

Cash, beginning of period                                           7,145                   -                     -
                                                          ---------------    ----------------     -----------------

Cash, end of period                                       $            62    $              -     $              62
                                                          ===============    ================     =================

Supplemental disclosure of cash flow information:

   Cash paid during the period for:
      Interest                                            $             -    $              -     $               -
                                                          ===============    ================     =================
      Income taxes                                        $             -    $              -     $               -
                                                          ===============    ================     =================

                            See accompanying notes to consolidated financial statements

                                                         5
</TABLE>
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

               For the Three Months ended March 31, 2002 and 2001,
                and for the Period from Inception, April 9, 1998,
                             through March 31, 2002


1.       Basis of Presentation, Capital Structure, and Significant Accounting
         Policies

         Basis of Presentation

         Malacology, Inc. (A Development Stage Enterprise) (the "Company") was
         incorporated on April 9, 1998 under the laws of the State of Nevada.
         The Company intends to develop operating opportunities through business
         combinations or mergers. To date, the Company has not conducted any
         significant operations, and its activities have focused primarily on
         organizational efforts, corporate compliance matters and locating
         potential merger candidates. Since the Company has not yet commenced
         any principal operations, and has not yet earned significant revenues,
         the Company is considered to be a development stage enterprise as of
         March 31, 2002.

         West Wing Holdings Acquisitions, Inc. ("West Wing") was incorporated in
         the State of Florida on December 14, 2001 as a wholly owned subsidiary
         of the Company. West Wing was formed with the objective of providing
         value added, low cost telecommunication services in foreign markets.
         West Wing has conducted no operations to date, and is a nonoperating
         shell company.

         The accompanying consolidated financial statements include the accounts
         of the Company and West Wing from the date of its formation.

         The accompanying unaudited consolidated financial statements have been
         prepared in accordance with accounting principles generally accepted in
         the United States of America for interim financial information and the
         instructions to Form 10-QSB. Accordingly, they do not include all the
         information and footnotes required by accounting principles generally
         accepted in the United States of America for complete financial
         statements. In the opinion of management, the interim financial
         statements include all adjustments considered necessary for a fair
         presentation of the Company's financial position, results of operations
         and cash flows for the three months ended March 31, 2002. These
         statements are not necessarily indicative of the results to be expected
         for the full fiscal year. These statements should be read in
         conjunction with the financial statements and notes thereto included in
         the Company's Form 10-KSB for the year ended December 31, 2001 as filed
         with the Securities and Exchange Commission.

                                       6
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

               For the Three Months ended March 31, 2002 and 2001,
                and for the Period from Inception, April 9, 1998,
                             through March 31, 2002


1.       Basis of Presentation, Capital Structure, and Significant Accounting
         Policies (continued)

         Capital Structure

         On April 10, 1998, the Company's Board of Directors approved the
         issuance of 1,000,000 shares of common stock to the Company's founders
         for services which were valued at a nominal amount approximating fair
         value ($1,000 recorded as general and administrative expenses in the
         accompanying statement of operations). Of these shares, 824,500 shares
         were issued to two officers of the Company, and as of December 31,
         2000, such shares were owned by one officer.

         In October 2001, the Company's then majority stockholder and sole
         officer and director and one other former stockholder sold 970,000
         shares of the Company's common stock to Contract Consultants
         International, Inc. ("CCI") for cash of $25,000. CCI sold the same
         970,000 shares of the Company's common stock to the Company's current
         President and sole director for $100,000 cash. Such transactions
         resulted in a change in control of the Company.

         The Company also granted stock options pursuant to an employment
         agreement that is described in Note 3.

         Going Concern and Management's Plans

         The Company has not commenced significant operations and has limited
         financial and other resources. Such matters raise substantial doubt
         about the Company's ability to continue as a going concern.
         Management's plans with respect to these conditions are to search for
         additional sources of debt and/or equity financing and new operating
         opportunities through business combinations or mergers. In the interim,
         the Company will require minimal overhead, and key administrative and
         management functions will be provided by consultants and stockholders.
         Accordingly, the accompanying financial statements have been presented
         under the assumption that the Company will continue as a going concern.

                                      7
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

               For the Three Months ended March 31, 2002 and 2001,
                and for the Period from Inception, April 9, 1998,
                             through March 31, 2002


1.       Basis of Presentation, Capital Structure, and Significant Accounting
         Policies (continued)

         Management Estimates

         The preparation of financial statements in conformity with accounting
         principles generally accepted in the United States of America requires
         management to make estimates and assumptions that affect the reported
         amounts of assets and liabilities, and disclosure of contingent assets
         and liabilities at the date of the financial statements, and the
         reported amounts of revenues and expenses during the reporting period.
         Actual results could differ from those estimates.

2.       Advances from Officer

         As of March 31, 2002, the Company has received advances from its
         President and sole director in the aggregate amount of $123,740. As of
         the date of this report, such advances are not subject to formal,
         written agreements, have no stated repayment terms, do not bear
         interest, and are not collateralized.

3.       Commitments

         Employment Agreements

         The Company has employment agreements with its President, who is the
         Company's sole director and majority stockholder, and its Chief
         Financial Officer. The agreements provide for minimum annual salaries
         aggregating $400,000 and are for terms ranging for two to five years.
         The agreements also provide for minimum severance payments to the
         officers equal to amounts ranging from $37,500 to $750,000 in the
         aggregate. The Company's President is entitled to receive annual
         bonuses equal to 60% of his then annual salary, provided that such
         bonus will be reduced to the extent that it exceeds the Company's net
         profit (as defined). Additionally, the Company's Chief Financial
         Officer is entitled to receive 25,000 shares of common stock and is
         entitled to receive 125,000 stock options, exercisable at $1.50 per
         share, at the conclusion of each of his first and second years of
         service. Effective June 10, 2002, the Company's Chief Financial Officer
         resigned.

         As of March 31, 2002, the Company has accrued salaries payable of
         $63,432, and such amount is included in accrued expenses in the
         accompanying consolidated balance sheet.

                                       8
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

               For the Three Months ended March 31, 2002 and 2001,
                and for the Period from Inception, April 9, 1998,
                             through March 31, 2002


3.       Commitments (continued)

         Consulting Agreement

         The Company has a one-year consulting agreement, maturing September
         2002, which requires payments of $15,000 per month and can be
         terminated by either party with thirty days written notice. The
         consulting agreement also provided an option to participate in a
         convertible debenture offering whereby $1,200 of convertible notes
         payable were issued by the Company (convertible into 1,200,000 shares
         of the Company's common stock). Effective May 31, 2002, the Company
         terminated this consulting agreement.

                                       9
<PAGE>

Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

         The following discussion contains certain forward-looking statements
that are subject to business and economic risks and uncertainties, and the
Company's actual results could differ materially from those forward-looking
statements. The following discussion regarding the financial statements of the
Company should be read in conjunction with the financial statements and notes
thereto.

BACKGROUND OF THE COMPANY

         The Company was organized under the Laws of the State of Nevada, on
April 9, 1998, as a blank check or shell company whose primary purpose is to
engage in a merger with, or acquisition of one or a small number of private
firms. Such firms are expected to be private corporations, partnerships or sole
proprietorships. From inception through the present time, the primary activity
of the Company has been directed towards organizational efforts, compliance
matters and locating potential merger candidates.

         On October 22, 2001, M. Richard Cutler, at that time a principal
shareholder of the Company and the Company's sole officer and director and Vi
Bui, at that time a principal shareholder of the Company, sold an aggregate of
970,000 shares of the Company's common stock to Contracts Consultants
International, Inc. ("CCI"), a Florida corporation. Simultaneously therewith,
CCI sold those same 970,000 shares to Mr. Vivek Rao. These shares represent 97%
of the issued and outstanding shares of the Company. As a result of the above
described transactions, Vivek R. Rao became the "control person" of the Company
as that term is defined in the Securities Act of 1933, as amended (the "Act").
Simultaneously with these transactions, the board of directors nominated Vivek
R. Rao to the board of directors and all former officers and directors resigned,
thereby leaving Mr. Rao the Company's sole director. Vivek R. Rao was then
appointed the Company's CEO, President, Secretary and Treasurer.

         In December 2001, we formed West Wing Holdings Acquisitions, Inc.
("West Wing"), a Florida corporation as a wholly owned subsidiary. The Company
previously announced that West Wing established initial operations in the
telecommunications industry. West Wing planned to enter the telecommunications
industry through the acquisition of certain assets in Eastern Europe. The
Company was unable to complete the acquisition of the targeted assets and is
currently seeking out other opportunities within and outside the
telecommunications industry. Accordingly, the Company is still a "blank check"
or "shell" company. At present, the Company has no business opportunities under
contemplation for acquisitions.

GENERAL OVERVIEW

         The Company's activities since inception have been limited to
organizational matters, compliance efforts and locating potential merger
candidates, and the Company has not engaged in any operating activity since its
inception.

         The Company has registered its Common Stock on a Form 10-SB
registration statement filed pursuant to the Securities Exchange Act of 1934
(the Exchange Act) and Rule 12(g) thereof. The Company files with the Securities
and Exchange Commission periodic reports under Rule 13(a) of the Exchange Act,
including quarterly reports on Form 10-QSB and annual reports on Form 10-KSB.

                                       10
<PAGE>

         The Company was formed to engage in a merger with or acquisition of an
unidentified foreign or domestic private company which desires to become a
reporting (public) company whose securities are qualified for trading in the
United States secondary market. The Company meets the definition of a blank
check company contained in Section 7(b)(3) of the Securities Act of 1933, as
amended.

         Management believes that there are perceived benefits to being a
reporting company with a class of publicly-traded securities which may be
attractive to foreign and domestic private companies.

         These benefits are commonly thought to include (1) the ability to use
registered securities to make acquisition of assets or businesses; (2) increased
visibility in the financial community; (3) the facilitation of borrowing from
financial institutions; (4) improved trading efficiency; (5) shareholder
liquidity; (6) greater ease in subsequently raising capital; (7) compensation of
key employees through options for stock for which there is a public market; (8)
enhanced corporate image; and, (9) a presence in the United States capital
market.

         A private company which may be interested in a business combination
with the Company may include (1) a company for which a primary purpose of
becoming public is the use of its securities for the acquisition of assets or
businesses; (2) a company which is unable to find an underwriter of its
securities or is unable to find an underwriter of securities on terms acceptable
to it; (3) a company which wishes to become public with less dilution of its
Common Stock than would occur normally upon an underwriting; (4) a company which
believes that it will be able to obtain investment capital on more favorable
terms after it has become public; (5) a foreign company which may wish an
initial entry into the United States securities market; (6) a special situation
company, such as a company seeking a public market to satisfy redemption
requirements under a qualified Employee Stock Option Plan; and, (7) a company
seeking one or more of the other benefits believed to attach to a public
company.

         The Company is authorized to enter into a definitive agreement with a
wide variety of private businesses without limitation as to their industry or
revenues. It is not possible at this time to predict with which private company,
if any, the Company will enter into a definitive agreement or what will be the
industry, operating history, revenues, future prospects or other characteristics
of that company.

         As of the date hereof, Management has not made any final decision
concerning, and has not entered into any agreements for, a business combination.
When any such agreement is reached or other material fact occurs, the Company
will file notice of such agreement or fact with the Securities and Exchange
Commission on Form 8-K. Persons reading this Form 10-QSB are advised to see if
the Company has subsequently filed a Form 8-K.

         As soon as the Company is eligible, it intends to apply to have its
Common Stock listed or admitted to quotation on the NASD OTC Bulletin Board or
its replacement, the BBX or, if it meets the financial and other requirements
thereof, on the Nasdaq Small Cap Market, National Market System, or other
regional or national exchange.

                                       11
<PAGE>

THREE MONTHS ENDED MARCH 31, 2002 COMPARED WITH THE PERIOD ENDED MARCH 31, 2001

         During the three months ended March 31, 2002 the Company incurred
general, administrative and consulting expenses in the amount of $173,270 as
compared to $1,558 for the same period ended March 31, 2001. The Company has
incurred these expenses in connection with its aggressive strategy to seek an
acquisition candidate. During the quarter ended March 31, 2002, the Company
incurred payroll costs of $95,148, consulting fees of $58,754, travel and
entertainment costs of $8,549, and interest on outstanding debentures of $3,143.

Liquidity

         The Company has financed its operations through advances from its
President and from the sale of convertible debentures. During October and
November 2001 the Company sold an aggregate of $11,475 of the Company's 5%
senior subordinated convertible debentures due December 31, 2002. The debentures
are convertible into the Company's Common Stock at $.001 per share.

         On November 30, 2001, the Company authorized the issuance of 8%
subordinated convertible debentures due June 30, 2003 in the aggregate amount of
$500,000. These debentures are convertible into the Company's Common Sock at
$.50 per share. As of March 31, 2002 the Company sold an aggregate of $150,000
of these debentures.

         At March 31, 2002 the Company had $62 in cash and total assets of
$6,455. As of that same date the Company had total current liabilities of
$238742, and had a working capital deficit of $234,050.

         As of March 31, 2002 the Company's total liabilities, including
non-current liabilities were $388,742 and the Company had a stockholder deficit
of $382,287.

         Our liquidity and capital resources could improve in the short term by
loans from related parties and private financing activities of both the
Company's equity and debt securities.

                                       12
<PAGE>

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings.

         There are no legal proceedings against the Company and the Company is
         unaware of any proceedings contemplated against it.

Item 2.  Changes in Securities.

         During the quarter ended March 31, 2002 the Company sold an aggregate
         of $50,000 of its 8% subordinated convertible debentures due June 30,
         2003 to 1 purchaser. These debentures are convertible into the
         Company's Common Stock at $.50 per share. As of March 31, 2002, the
         Company sold an aggregate of $150,000 of these debentures.

Item 3.  Defaults Upon Senior Securities.

         None.

Item 4.  Submission of Matters to a Vote of Security Holders.

         No matters were submitted to the security holders for a vote.

Item 5.  Other Information.

         Effective June 10, 2002, Mr. Kenneth O'Rorke, the Company's Chief
         Financial Officer, tendered his resignation to the Company. In
         connection with his resignation, the Company agreed to issue Mr.
         O'Rorke twenty-five thousand (25,000) shares of the Company's Common
         Stock and a stock option exercisable for three (3) years to purchase
         125,000 shares of the Company's Common Stock at a cost of $1.50 per
         share. The issuance of the shares and option is contingent upon the
         Company's acquisition of certain assets from an unrelated third party.

Item 6.  Exhibits and Reports on Form 8-K.

         (a)      Exhibits

                  None.

         (b)      Reports on Form 8-K.

                  None.

                                       13
<PAGE>

                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                                    MALACOLOGY, INC.


Dated:  June 11, 2002                               By: /s/ Vivek R. Rao
                                                       -------------------------
                                                        Vivek R. Rao
                                                        Chief Executive Officer

                                       14